Share Price and Basic Stock Data
Last Updated: December 23, 2025, 11:29 pm
| PEG Ratio | 3.53 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Elantas Beck India Ltd operates in the organic chemicals sector, specializing in the production of high-performance coatings and other industrial chemicals. As of June 2023, the company’s stock price stood at ₹9,051, with a market capitalization of ₹7,175 Cr. The company has shown a consistent upward trajectory in revenue, reporting sales of ₹645 Cr in December 2022, which climbed to ₹680 Cr by December 2023. This growth trajectory appears robust, with trailing twelve-month (TTM) revenue reaching ₹797 Cr. The quarterly sales figures illustrate this momentum, with June 2023 sales at ₹173 Cr, slightly up from ₹169 Cr in March 2023. However, the slight decline to ₹163 Cr in September 2023 raises questions about potential seasonal fluctuations or market challenges. Overall, Elantas Beck seems well-positioned to capitalize on growing demand in the chemical sector, although maintaining this growth will require vigilant market analysis and strategic agility.
Profitability and Efficiency Metrics
The profitability of Elantas Beck is noteworthy, particularly when considering its operating profit margin (OPM) of 19%. The company reported a net profit of ₹133 Cr, reflecting a solid net profit margin of approximately 18.64% for the trailing twelve months. This metric is particularly impressive compared to industry averages, indicating efficient cost management and strong pricing power. The return on equity (ROE) stood at 17.4%, suggesting that the company is effectively generating returns on shareholder investments. Efficiency metrics also shine, with a return on capital employed (ROCE) at 23%, indicating that Elantas Beck is utilizing its capital efficiently to generate profits. However, the fluctuating OPM, which peaked at 23% in September 2023 before declining to 20% in December 2023, hints at potential volatility in cost structures or pricing pressures that could impact future profitability.
Balance Sheet Strength and Financial Ratios
Elantas Beck’s balance sheet reflects a robust financial position, characterized by zero borrowings, which provides a significant cushion against interest rate fluctuations and enhances financial stability. The company’s reserves have steadily increased, reaching ₹925 Cr as of June 2025, showcasing a prudent approach to retaining earnings for future growth. The interest coverage ratio (ICR) is particularly striking at 302.41x, indicating that the company can easily cover its interest obligations, further emphasizing its strong financial health. Additionally, the price-to-book value ratio (P/BV) of 11.68x suggests that the stock may be trading at a premium, reflecting investor confidence in its future growth prospects. However, a high P/BV could also indicate that the stock is overvalued, which is a consideration for potential investors looking for entry points.
Shareholding Pattern and Investor Confidence
Elantas Beck’s shareholding pattern indicates a strong commitment from its promoters, who hold 75% of the company. This level of promoter ownership often instills confidence among retail investors, as it suggests alignment of interests between management and shareholders. Institutional investors, particularly domestic institutional investors (DIIs), held 12.17% of the shares as of June 2025, reflecting a growing interest from professional investors. However, foreign institutional investors (FIIs) have seen their stake dwindle to just 0.04%, which may raise red flags about international confidence in the stock. The number of shareholders has increased steadily, rising to 8,892 by June 2025, indicating a growing retail interest. This trend could be a positive sign, as a broader shareholder base often contributes to stability in stock performance.
Outlook, Risks, and Final Insight
Looking ahead, Elantas Beck India Ltd presents a compelling investment case, but not without risks. The company’s strong fundamentals, including zero debt and impressive profitability metrics, suggest a solid foundation. However, the potential for fluctuating margins and the recent decline in sales growth may pose challenges. Investors should also be cautious of the high P/BV ratio, which could indicate overvaluation, especially if growth does not sustain. Moreover, the significant drop in FII participation may reflect external concerns about market conditions or company-specific risks. In summary, while Elantas Beck appears strong in many respects, its future performance will depend on maintaining operational efficiency, navigating market dynamics, and sustaining investor confidence amidst evolving economic conditions. Investors should weigh these factors carefully, considering both the potential rewards and the inherent risks associated with this stock.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujchem Distillers India Ltd | 94.9 Cr. | 266 | 456/243 | 221 | 392 | 0.04 % | 0.21 % | 0.09 % | 1.00 |
| Elantas Beck India Ltd | 7,633 Cr. | 9,628 | 14,250/8,150 | 55.2 | 1,177 | 0.08 % | 23.0 % | 17.4 % | 10.0 |
| Crestchem Ltd | 34.7 Cr. | 116 | 329/109 | 17.2 | 26.9 | 0.86 % | 59.9 % | 44.1 % | 10.0 |
| Chemiesynth (Vapi) Ltd | 11.6 Cr. | 37.6 | 37.6/35.8 | 32.8 | 0.00 % | 3.10 % | 0.99 % | 10.0 | |
| ARCL Organics Ltd | 320 Cr. | 400 | 435/163 | 17.8 | 108 | 0.00 % | 20.4 % | 16.8 % | 10.0 |
| Industry Average | 4,623.83 Cr | 1,539.98 | 64.30 | 334.84 | 0.41% | 14.71% | 10.69% | 7.56 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 171 | 153 | 165 | 169 | 173 | 163 | 174 | 177 | 191 | 184 | 197 | 206 | 210 |
| Expenses | 141 | 129 | 136 | 134 | 138 | 126 | 138 | 139 | 153 | 150 | 162 | 166 | 170 |
| Operating Profit | 30 | 24 | 29 | 36 | 35 | 37 | 36 | 38 | 39 | 33 | 35 | 40 | 40 |
| OPM % | 17% | 16% | 17% | 21% | 20% | 23% | 20% | 21% | 20% | 18% | 18% | 20% | 19% |
| Other Income | 1 | 14 | 10 | 8 | 15 | 12 | 17 | 15 | 17 | 12 | 10 | 9 | 18 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 5 | 5 | 5 |
| Profit before tax | 28 | 35 | 35 | 40 | 47 | 47 | 49 | 49 | 52 | 42 | 40 | 44 | 53 |
| Tax % | 26% | 22% | 25% | 26% | 25% | 25% | 25% | 25% | 20% | 25% | 26% | 26% | 26% |
| Net Profit | 21 | 27 | 26 | 30 | 35 | 35 | 37 | 37 | 42 | 31 | 30 | 33 | 39 |
| EPS in Rs | 25.95 | 34.07 | 33.40 | 37.91 | 44.68 | 43.93 | 46.67 | 46.56 | 52.79 | 39.19 | 37.51 | 41.46 | 49.56 |
Last Updated: August 19, 2025, 7:30 pm
Below is a detailed analysis of the quarterly data for Elantas Beck India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 210.00 Cr.. The value appears strong and on an upward trend. It has increased from 206.00 Cr. (Mar 2025) to 210.00 Cr., marking an increase of 4.00 Cr..
- For Expenses, as of Jun 2025, the value is 170.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 166.00 Cr. (Mar 2025) to 170.00 Cr., marking an increase of 4.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 40.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 40.00 Cr..
- For OPM %, as of Jun 2025, the value is 19.00%. The value appears to be declining and may need further review. It has decreased from 20.00% (Mar 2025) to 19.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is 18.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.00 Cr. (Mar 2025) to 18.00 Cr., marking an increase of 9.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 53.00 Cr.. The value appears strong and on an upward trend. It has increased from 44.00 Cr. (Mar 2025) to 53.00 Cr., marking an increase of 9.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 26.00%.
- For Net Profit, as of Jun 2025, the value is 39.00 Cr.. The value appears strong and on an upward trend. It has increased from 33.00 Cr. (Mar 2025) to 39.00 Cr., marking an increase of 6.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 49.56. The value appears strong and on an upward trend. It has increased from 41.46 (Mar 2025) to 49.56, marking an increase of 8.10.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:48 am
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 304 | 341 | 344 | 365 | 383 | 409 | 394 | 383 | 522 | 645 | 680 | 749 | 830 |
| Expenses | 265 | 299 | 282 | 287 | 304 | 344 | 340 | 313 | 444 | 535 | 537 | 604 | 667 |
| Operating Profit | 39 | 42 | 62 | 79 | 78 | 65 | 54 | 70 | 78 | 110 | 143 | 144 | 162 |
| OPM % | 13% | 12% | 18% | 22% | 20% | 16% | 14% | 18% | 15% | 17% | 21% | 19% | 20% |
| Other Income | 11 | 8 | 6 | 8 | 9 | 31 | 18 | 22 | 25 | 32 | 53 | 55 | 44 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Depreciation | 5 | 5 | 6 | 5 | 6 | 7 | 7 | 12 | 12 | 12 | 12 | 15 | 20 |
| Profit before tax | 45 | 45 | 62 | 81 | 81 | 89 | 64 | 80 | 91 | 129 | 184 | 183 | 186 |
| Tax % | 29% | 30% | 32% | 33% | 32% | 26% | 22% | 23% | 27% | 24% | 25% | 24% | |
| Net Profit | 32 | 32 | 42 | 54 | 55 | 66 | 50 | 62 | 67 | 98 | 137 | 140 | 138 |
| EPS in Rs | 40.05 | 39.87 | 52.68 | 68.73 | 69.48 | 82.99 | 62.51 | 77.90 | 84.36 | 123.34 | 173.19 | 176.04 | 174.27 |
| Dividend Payout % | 137% | 11% | 9% | 7% | 6% | 5% | 8% | 6% | 6% | 4% | 3% | 4% |
YoY Net Profit Growth
| Year |
|---|
| YoY Net Profit Growth (%) |
| Change in YoY Net Profit Growth (%) |
No data available for trend analysis.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 14% |
| 3 Years: | 13% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 23% |
| 3 Years: | 33% |
| TTM: | -12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 34% |
| 3 Years: | 34% |
| 1 Year: | -9% |
| Return on Equity | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 17% |
| 3 Years: | 18% |
| Last Year: | 17% |
Last Updated: September 5, 2025, 3:21 pm
Balance Sheet
Last Updated: August 11, 2025, 3:52 pm
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Reserves | 100 | 128 | 164 | 214 | 270 | 331 | 376 | 434 | 497 | 591 | 724 | 859 | 925 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 93 | 57 | 64 | 70 | 70 | 76 | 72 | 95 | 114 | 119 | 149 | 148 | 163 |
| Total Liabilities | 201 | 192 | 236 | 291 | 348 | 415 | 456 | 536 | 618 | 717 | 881 | 1,015 | 1,096 |
| Fixed Assets | 48 | 45 | 45 | 36 | 40 | 70 | 110 | 103 | 98 | 98 | 99 | 223 | 232 |
| CWIP | 0 | 1 | 0 | 5 | 15 | 0 | 10 | 18 | 19 | 13 | 17 | 19 | 18 |
| Investments | 45 | 30 | 64 | 109 | 139 | 174 | 160 | 218 | 261 | 356 | 517 | 379 | 527 |
| Other Assets | 108 | 116 | 126 | 140 | 154 | 171 | 176 | 198 | 240 | 250 | 247 | 395 | 319 |
| Total Assets | 201 | 192 | 236 | 291 | 348 | 415 | 456 | 536 | 618 | 717 | 881 | 1,015 | 1,096 |
Below is a detailed analysis of the balance sheet data for Elantas Beck India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Equity Capital, as of Jun 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 8.00 Cr..
- For Reserves, as of Jun 2025, the value is 925.00 Cr.. The value appears strong and on an upward trend. It has increased from 859.00 Cr. (Dec 2024) to 925.00 Cr., marking an increase of 66.00 Cr..
- For Borrowings, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
- For Other Liabilities, as of Jun 2025, the value is 163.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 148.00 Cr. (Dec 2024) to 163.00 Cr., marking an increase of 15.00 Cr..
- For Total Liabilities, as of Jun 2025, the value is 1,096.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,015.00 Cr. (Dec 2024) to 1,096.00 Cr., marking an increase of 81.00 Cr..
- For Fixed Assets, as of Jun 2025, the value is 232.00 Cr.. The value appears strong and on an upward trend. It has increased from 223.00 Cr. (Dec 2024) to 232.00 Cr., marking an increase of 9.00 Cr..
- For CWIP, as of Jun 2025, the value is 18.00 Cr.. The value appears to be declining and may need further review. It has decreased from 19.00 Cr. (Dec 2024) to 18.00 Cr., marking a decrease of 1.00 Cr..
- For Investments, as of Jun 2025, the value is 527.00 Cr.. The value appears strong and on an upward trend. It has increased from 379.00 Cr. (Dec 2024) to 527.00 Cr., marking an increase of 148.00 Cr..
- For Other Assets, as of Jun 2025, the value is 319.00 Cr.. The value appears to be declining and may need further review. It has decreased from 395.00 Cr. (Dec 2024) to 319.00 Cr., marking a decrease of 76.00 Cr..
- For Total Assets, as of Jun 2025, the value is 1,096.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,015.00 Cr. (Dec 2024) to 1,096.00 Cr., marking an increase of 81.00 Cr..
Notably, the Reserves (925.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 39.00 | 42.00 | 62.00 | 79.00 | 78.00 | 65.00 | 54.00 | 70.00 | 78.00 | 110.00 | 143.00 | 144.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 56 | 53 | 59 | 53 | 70 | 75 | 57 | 67 | 61 | 58 | 55 | 62 |
| Inventory Days | 81 | 84 | 85 | 100 | 75 | 74 | 77 | 89 | 95 | 73 | 68 | 78 |
| Days Payable | 44 | 55 | 64 | 73 | 73 | 71 | 56 | 103 | 86 | 67 | 81 | 76 |
| Cash Conversion Cycle | 93 | 82 | 80 | 80 | 71 | 78 | 77 | 54 | 70 | 64 | 41 | 64 |
| Working Capital Days | 9 | 58 | 55 | 55 | 62 | 69 | 59 | 46 | 57 | 48 | 33 | 56 |
| ROCE % | 34% | 35% | 40% | 41% | 33% | 23% | 18% | 19% | 17% | 22% | 28% | 23% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 651,246 | 0.92 | 632.61 | 614,625 | 2025-11-03 21:48:08 | 5.96% |
| Tata Small Cap Fund | 209,256 | 1.78 | 203.27 | 215,767 | 2025-11-03 21:48:08 | -3.02% |
| Tata Large & Mid Cap Fund | 94,264 | 1.05 | 91.57 | N/A | N/A | N/A |
| Union Small Cap Fund | 6,296 | 0.34 | 6.12 | 6,814 | 2025-12-14 03:22:17 | -7.6% |
| Union Retirement Fund | 1,111 | 0.57 | 1.08 | 1,242 | 2025-12-15 02:08:30 | -10.55% |
Key Financial Ratios
| Month | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 176.05 | 173.18 | 123.34 | 84.36 | 77.91 |
| Diluted EPS (Rs.) | 176.05 | 173.18 | 123.34 | 84.36 | 77.91 |
| Cash EPS (Rs.) | 195.01 | 188.19 | 138.97 | 99.64 | 92.67 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1093.78 | 923.34 | 755.07 | 636.59 | 557.02 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1093.78 | 923.34 | 755.07 | 636.59 | 557.02 |
| Dividend / Share (Rs.) | 7.50 | 5.00 | 5.00 | 5.00 | 5.00 |
| Revenue From Operations / Share (Rs.) | 944.17 | 857.61 | 813.23 | 658.62 | 483.28 |
| PBDIT / Share (Rs.) | 251.19 | 247.35 | 165.77 | 119.32 | 116.22 |
| PBIT / Share (Rs.) | 232.23 | 232.34 | 150.14 | 104.05 | 101.46 |
| PBT / Share (Rs.) | 231.40 | 231.62 | 162.89 | 115.26 | 101.18 |
| Net Profit / Share (Rs.) | 176.05 | 173.18 | 123.34 | 84.36 | 77.91 |
| PBDIT Margin (%) | 26.60 | 28.84 | 20.38 | 18.11 | 24.04 |
| PBIT Margin (%) | 24.59 | 27.09 | 18.46 | 15.79 | 20.99 |
| PBT Margin (%) | 24.50 | 27.00 | 20.02 | 17.50 | 20.93 |
| Net Profit Margin (%) | 18.64 | 20.19 | 15.16 | 12.80 | 16.12 |
| Return on Networth / Equity (%) | 16.09 | 18.75 | 16.33 | 13.25 | 13.98 |
| Return on Capital Employeed (%) | 20.63 | 24.34 | 19.24 | 15.79 | 17.63 |
| Return On Assets (%) | 13.74 | 15.59 | 13.62 | 10.81 | 11.51 |
| Asset Turnover Ratio (%) | 0.78 | 0.85 | 0.96 | 0.90 | 0.77 |
| Current Ratio (X) | 6.26 | 6.12 | 5.92 | 4.75 | 4.65 |
| Quick Ratio (X) | 5.49 | 5.53 | 5.11 | 3.87 | 3.99 |
| Inventory Turnover Ratio (X) | 8.90 | 8.88 | 5.21 | 5.25 | 4.18 |
| Dividend Payout Ratio (NP) (%) | 2.84 | 2.88 | 4.05 | 5.92 | 6.41 |
| Dividend Payout Ratio (CP) (%) | 2.56 | 2.65 | 3.59 | 5.01 | 5.39 |
| Earning Retention Ratio (%) | 97.16 | 97.12 | 95.95 | 94.08 | 93.59 |
| Cash Earning Retention Ratio (%) | 97.44 | 97.35 | 96.41 | 94.99 | 94.61 |
| Interest Coverage Ratio (X) | 302.41 | 343.36 | 212.79 | 379.45 | 422.05 |
| Interest Coverage Ratio (Post Tax) (X) | 212.94 | 241.41 | 141.97 | 232.60 | 283.93 |
| Enterprise Value (Cr.) | 9977.38 | 6676.60 | 3404.85 | 2895.59 | 2157.70 |
| EV / Net Operating Revenue (X) | 13.33 | 9.82 | 5.28 | 5.55 | 5.63 |
| EV / EBITDA (X) | 50.10 | 34.05 | 25.91 | 30.61 | 23.42 |
| MarketCap / Net Operating Revenue (X) | 13.53 | 9.90 | 5.35 | 5.58 | 5.70 |
| Retention Ratios (%) | 97.15 | 97.11 | 95.94 | 94.07 | 93.58 |
| Price / BV (X) | 11.68 | 9.20 | 5.76 | 5.77 | 4.95 |
| Price / Net Operating Revenue (X) | 13.53 | 9.90 | 5.35 | 5.58 | 5.70 |
| EarningsYield | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 |
After reviewing the key financial ratios for Elantas Beck India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Dec 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Dec 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Dec 24, the value is 176.05. This value is within the healthy range. It has increased from 173.18 (Dec 23) to 176.05, marking an increase of 2.87.
- For Diluted EPS (Rs.), as of Dec 24, the value is 176.05. This value is within the healthy range. It has increased from 173.18 (Dec 23) to 176.05, marking an increase of 2.87.
- For Cash EPS (Rs.), as of Dec 24, the value is 195.01. This value is within the healthy range. It has increased from 188.19 (Dec 23) to 195.01, marking an increase of 6.82.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Dec 24, the value is 1,093.78. It has increased from 923.34 (Dec 23) to 1,093.78, marking an increase of 170.44.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Dec 24, the value is 1,093.78. It has increased from 923.34 (Dec 23) to 1,093.78, marking an increase of 170.44.
- For Dividend / Share (Rs.), as of Dec 24, the value is 7.50. This value exceeds the healthy maximum of 3. It has increased from 5.00 (Dec 23) to 7.50, marking an increase of 2.50.
- For Revenue From Operations / Share (Rs.), as of Dec 24, the value is 944.17. It has increased from 857.61 (Dec 23) to 944.17, marking an increase of 86.56.
- For PBDIT / Share (Rs.), as of Dec 24, the value is 251.19. This value is within the healthy range. It has increased from 247.35 (Dec 23) to 251.19, marking an increase of 3.84.
- For PBIT / Share (Rs.), as of Dec 24, the value is 232.23. This value is within the healthy range. It has decreased from 232.34 (Dec 23) to 232.23, marking a decrease of 0.11.
- For PBT / Share (Rs.), as of Dec 24, the value is 231.40. This value is within the healthy range. It has decreased from 231.62 (Dec 23) to 231.40, marking a decrease of 0.22.
- For Net Profit / Share (Rs.), as of Dec 24, the value is 176.05. This value is within the healthy range. It has increased from 173.18 (Dec 23) to 176.05, marking an increase of 2.87.
- For PBDIT Margin (%), as of Dec 24, the value is 26.60. This value is within the healthy range. It has decreased from 28.84 (Dec 23) to 26.60, marking a decrease of 2.24.
- For PBIT Margin (%), as of Dec 24, the value is 24.59. This value exceeds the healthy maximum of 20. It has decreased from 27.09 (Dec 23) to 24.59, marking a decrease of 2.50.
- For PBT Margin (%), as of Dec 24, the value is 24.50. This value is within the healthy range. It has decreased from 27.00 (Dec 23) to 24.50, marking a decrease of 2.50.
- For Net Profit Margin (%), as of Dec 24, the value is 18.64. This value exceeds the healthy maximum of 10. It has decreased from 20.19 (Dec 23) to 18.64, marking a decrease of 1.55.
- For Return on Networth / Equity (%), as of Dec 24, the value is 16.09. This value is within the healthy range. It has decreased from 18.75 (Dec 23) to 16.09, marking a decrease of 2.66.
- For Return on Capital Employeed (%), as of Dec 24, the value is 20.63. This value is within the healthy range. It has decreased from 24.34 (Dec 23) to 20.63, marking a decrease of 3.71.
- For Return On Assets (%), as of Dec 24, the value is 13.74. This value is within the healthy range. It has decreased from 15.59 (Dec 23) to 13.74, marking a decrease of 1.85.
- For Asset Turnover Ratio (%), as of Dec 24, the value is 0.78. It has decreased from 0.85 (Dec 23) to 0.78, marking a decrease of 0.07.
- For Current Ratio (X), as of Dec 24, the value is 6.26. This value exceeds the healthy maximum of 3. It has increased from 6.12 (Dec 23) to 6.26, marking an increase of 0.14.
- For Quick Ratio (X), as of Dec 24, the value is 5.49. This value exceeds the healthy maximum of 2. It has decreased from 5.53 (Dec 23) to 5.49, marking a decrease of 0.04.
- For Inventory Turnover Ratio (X), as of Dec 24, the value is 8.90. This value exceeds the healthy maximum of 8. It has increased from 8.88 (Dec 23) to 8.90, marking an increase of 0.02.
- For Dividend Payout Ratio (NP) (%), as of Dec 24, the value is 2.84. This value is below the healthy minimum of 20. It has decreased from 2.88 (Dec 23) to 2.84, marking a decrease of 0.04.
- For Dividend Payout Ratio (CP) (%), as of Dec 24, the value is 2.56. This value is below the healthy minimum of 20. It has decreased from 2.65 (Dec 23) to 2.56, marking a decrease of 0.09.
- For Earning Retention Ratio (%), as of Dec 24, the value is 97.16. This value exceeds the healthy maximum of 70. It has increased from 97.12 (Dec 23) to 97.16, marking an increase of 0.04.
- For Cash Earning Retention Ratio (%), as of Dec 24, the value is 97.44. This value exceeds the healthy maximum of 70. It has increased from 97.35 (Dec 23) to 97.44, marking an increase of 0.09.
- For Interest Coverage Ratio (X), as of Dec 24, the value is 302.41. This value is within the healthy range. It has decreased from 343.36 (Dec 23) to 302.41, marking a decrease of 40.95.
- For Interest Coverage Ratio (Post Tax) (X), as of Dec 24, the value is 212.94. This value is within the healthy range. It has decreased from 241.41 (Dec 23) to 212.94, marking a decrease of 28.47.
- For Enterprise Value (Cr.), as of Dec 24, the value is 9,977.38. It has increased from 6,676.60 (Dec 23) to 9,977.38, marking an increase of 3,300.78.
- For EV / Net Operating Revenue (X), as of Dec 24, the value is 13.33. This value exceeds the healthy maximum of 3. It has increased from 9.82 (Dec 23) to 13.33, marking an increase of 3.51.
- For EV / EBITDA (X), as of Dec 24, the value is 50.10. This value exceeds the healthy maximum of 15. It has increased from 34.05 (Dec 23) to 50.10, marking an increase of 16.05.
- For MarketCap / Net Operating Revenue (X), as of Dec 24, the value is 13.53. This value exceeds the healthy maximum of 3. It has increased from 9.90 (Dec 23) to 13.53, marking an increase of 3.63.
- For Retention Ratios (%), as of Dec 24, the value is 97.15. This value exceeds the healthy maximum of 70. It has increased from 97.11 (Dec 23) to 97.15, marking an increase of 0.04.
- For Price / BV (X), as of Dec 24, the value is 11.68. This value exceeds the healthy maximum of 3. It has increased from 9.20 (Dec 23) to 11.68, marking an increase of 2.48.
- For Price / Net Operating Revenue (X), as of Dec 24, the value is 13.53. This value exceeds the healthy maximum of 3. It has increased from 9.90 (Dec 23) to 13.53, marking an increase of 3.63.
- For EarningsYield, as of Dec 24, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Dec 23) to 0.01, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Elantas Beck India Ltd:
- Net Profit Margin: 18.64%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 20.63% (Industry Average ROCE: 14.71%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 16.09% (Industry Average ROE: 10.69%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 212.94
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 5.49
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 55.2 (Industry average Stock P/E: 64.3)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 18.64%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Organic - Others | 147, Mumbai-Pune Road, Pimpri, Pune Maharashtra 411018 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Martin Babilas | Chairman |
| Mr. Anurag Roy | Managing Director |
| Mr. Nandkumar Dhekne | Director |
| Mrs. Usha Rajeev | Director |
| Mr. Ravindra Kumar | Director |
| Mr. Sujjain Talwar | Director |
| Mr. Stefan Genten | Alternate Director |
FAQ
What is the intrinsic value of Elantas Beck India Ltd?
Elantas Beck India Ltd's intrinsic value (as of 23 December 2025) is 9051.11 which is 5.99% lower the current market price of 9,628.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 7,633 Cr. market cap, FY2025-2026 high/low of 14,250/8,150, reserves of ₹925 Cr, and liabilities of 1,096 Cr.
What is the Market Cap of Elantas Beck India Ltd?
The Market Cap of Elantas Beck India Ltd is 7,633 Cr..
What is the current Stock Price of Elantas Beck India Ltd as on 23 December 2025?
The current stock price of Elantas Beck India Ltd as on 23 December 2025 is 9,628.
What is the High / Low of Elantas Beck India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Elantas Beck India Ltd stocks is 14,250/8,150.
What is the Stock P/E of Elantas Beck India Ltd?
The Stock P/E of Elantas Beck India Ltd is 55.2.
What is the Book Value of Elantas Beck India Ltd?
The Book Value of Elantas Beck India Ltd is 1,177.
What is the Dividend Yield of Elantas Beck India Ltd?
The Dividend Yield of Elantas Beck India Ltd is 0.08 %.
What is the ROCE of Elantas Beck India Ltd?
The ROCE of Elantas Beck India Ltd is 23.0 %.
What is the ROE of Elantas Beck India Ltd?
The ROE of Elantas Beck India Ltd is 17.4 %.
What is the Face Value of Elantas Beck India Ltd?
The Face Value of Elantas Beck India Ltd is 10.0.